Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Stella

Home/Meningioma/

View on ClinicalTrials.gov

Recruiting

Back to Meningioma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

France

Assistance Publique Hôpitaux de Marseille, Marseille

Key details

Phase

Early testing

Sponsor

Assistance Publique Hopitaux De Marseille

Enrollment target

~25 participants

Started

September 2019

Primary completion

January 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.